Moving complex spine to ASCs saves 60%, but professionals warn that standard facilities aren't ready, as it takes ...
The FDA approved Itvisma gene therapy for patients aged 2 years and older with spinal muscular atrophy and confirmed SMN1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback